真实世界证据研究发现，接受阿伐糖苷酶α治疗的庞贝病患者未出现新发糖尿病或药物相关高血糖症。
Real-world evidence study finds no new-onset diabetes or drug-related hyperglycemia in Pompe disease patients treated with avalglucosidase alfa.
作者信息
Dumitriu Alexandra, Lucas Ann, Colzani Raffaella
机构信息
Sanofi, Cambridge, MA, USA.
出版信息
Mol Genet Metab Rep. 2024 Feb 20;38:101064. doi: 10.1016/j.ymgmr.2024.101064. eCollection 2024 Mar.
Abstract
Avalglucosidase alfa therapy for Pompe disease is diluted in dextrose 5% solution in water (D5W) for infusion, which raises questions about the potential for hyperglycemia or worsening diabetes. Using United States insurance claims data, we assessed the impact of biweekly infusions on hyperglycemia, new-onset diabetes mellitus, insulin resistance, and prediabetes in patients with Pompe disease. After starting avalglucosidase alfa treatment, 1 of 26 patients had one claim for hyperglycemia, which was attributed to acute pancreatitis.
摘要
用于庞贝病治疗的阿伐糖苷酶α在5%葡萄糖水溶液（D5W）中稀释后输注，这引发了关于高血糖或糖尿病病情恶化可能性的问题。利用美国保险理赔数据，我们评估了每两周一次的输注对庞贝病患者高血糖、新发糖尿病、胰岛素抵抗和糖尿病前期的影响。开始阿伐糖苷酶α治疗后，26名患者中有1名有一次高血糖理赔记录，该高血糖归因于急性胰腺炎。
相似文献
1
Real-world evidence study finds no new-onset diabetes or drug-related hyperglycemia in Pompe disease patients treated with avalglucosidase alfa.真实世界证据研究发现，接受阿伐糖苷酶α治疗的庞贝病患者未出现新发糖尿病或药物相关高血糖症。
Mol Genet Metab Rep. 2024 Feb 20;38:101064. doi: 10.1016/j.ymgmr.2024.101064. eCollection 2024 Mar.
2
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.阿伐糖苷酶α与糖苷酶α治疗晚发型庞贝病患者的安全性和有效性比较（COMET）：一项3期随机多中心试验
Lancet Neurol. 2021 Dec;20(12):1012-1026. doi: 10.1016/S1474-4422(21)00241-6.
3
Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa.一系列晚发型庞贝病患者从阿糖苷酶α转换为阿伐糖苷酶α后的真实世界结果。
Front Genet. 2024 Jan 19;15:1309146. doi: 10.3389/fgene.2024.1309146. eCollection 2024.
4
Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial.阿伐糖苷酶α治疗初治晚发性庞贝病成人患者的疾病特异性和一般患者报告结局的影响与阿糖苷酶α相比：来自 3 期 COMET 试验的有意义变化分析。
Mol Genet Metab. 2024 Feb;141(2):108121. doi: 10.1016/j.ymgme.2023.108121. Epub 2023 Dec 27.
5
Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.新型酶替代疗法 avalglucosidase alfa（neoGAA）在初治和已接受 alglucosidase alfa 治疗的晚发性庞贝病患者中的安全性、耐受性、药代动力学、药效学和探索性疗效：一项开放标签、多中心、多国、递增剂量的 1 期研究。
Neuromuscul Disord. 2019 Mar;29(3):167-186. doi: 10.1016/j.nmd.2018.12.004. Epub 2018 Dec 17.
6
Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report.阿伐糖苷酶α在婴儿型庞贝病患者中安全性和有效性的2期开放标签Mini-COMET研究：6个月主要分析报告
Genet Med. 2023 Feb;25(2):100328. doi: 10.1016/j.gim.2022.10.010. Epub 2022 Dec 21.
7
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.阿伐糖苷酶 α治疗晚发性庞贝病患者 97 周的疗效和安全性：一项 3 期随机临床试验。
JAMA Neurol. 2023 Jun 1;80(6):558-567. doi: 10.1001/jamaneurol.2023.0552.
8
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease.阿伐糖苷酶α治疗晚发性庞贝病患者的长期安全性和疗效。
Neurology. 2022 Aug 1;99(5):e536-e548. doi: 10.1212/WNL.0000000000200746.
9
Avalglucosidase alfa: First Approval.依帕司他：美国首次批准
Drugs. 2021 Oct;81(15):1803-1809. doi: 10.1007/s40265-021-01600-3.
10
Transcriptomic characterization of clinical skeletal muscle biopsy from late-onset Pompe patients.迟发性庞贝病患者临床骨骼肌活检的转录组特征。
Mol Genet Metab. 2023 Mar;138(3):107526. doi: 10.1016/j.ymgme.2023.107526. Epub 2023 Jan 25.
本文引用的文献
1
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.阿伐糖苷酶 α治疗晚发性庞贝病患者 97 周的疗效和安全性：一项 3 期随机临床试验。
JAMA Neurol. 2023 Jun 1;80(6):558-567. doi: 10.1001/jamaneurol.2023.0552.
2
Simplifying carb counting: A randomized controlled study - Feasibility and efficacy of an individualized, simple, patient-centred carb counting tool.简化碳水化合物计数：一项随机对照研究 - 个体化、简单、以患者为中心的碳水化合物计数工具的可行性和疗效。
Endocrinol Diabetes Metab. 2023 Mar;6(2):e411. doi: 10.1002/edm2.411. Epub 2023 Feb 7.
3
Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report.阿伐糖苷酶α在婴儿型庞贝病患者中安全性和有效性的2期开放标签Mini-COMET研究：6个月主要分析报告
Genet Med. 2023 Feb;25(2):100328. doi: 10.1016/j.gim.2022.10.010. Epub 2022 Dec 21.
4
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease.阿伐糖苷酶α治疗晚发性庞贝病患者的长期安全性和疗效。
Neurology. 2022 Aug 1;99(5):e536-e548. doi: 10.1212/WNL.0000000000200746.
5
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.阿伐糖苷酶α与糖苷酶α治疗晚发型庞贝病患者的安全性和有效性比较（COMET）：一项3期随机多中心试验
Lancet Neurol. 2021 Dec;20(12):1012-1026. doi: 10.1016/S1474-4422(21)00241-6.
6
Stress Hyperglycemia Is Independently Associated with Persistent Organ Failure in Acute Pancreatitis.应激性高血糖与急性胰腺炎持续性器官衰竭独立相关。
Dig Dis Sci. 2022 May;67(5):1879-1889. doi: 10.1007/s10620-021-06982-8. Epub 2021 May 3.
7
Glucose Counter-regulation After Acute Pancreatitis.急性胰腺炎后葡萄糖的反调节作用。
Pancreas. 2019 May/Jun;48(5):670-681. doi: 10.1097/MPA.0000000000001318.
8
Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report.成人糖尿病或糖尿病前期的营养治疗：共识报告。
Diabetes Care. 2019 May;42(5):731-754. doi: 10.2337/dci19-0014. Epub 2019 Apr 18.
9
Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.新型酶替代疗法 avalglucosidase alfa（neoGAA）在初治和已接受 alglucosidase alfa 治疗的晚发性庞贝病患者中的安全性、耐受性、药代动力学、药效学和探索性疗效：一项开放标签、多中心、多国、递增剂量的 1 期研究。
Neuromuscul Disord. 2019 Mar;29(3):167-186. doi: 10.1016/j.nmd.2018.12.004. Epub 2018 Dec 17.
10
Glycan structure determinants for cation-independent mannose 6-phosphate receptor binding and cellular uptake of a recombinant protein.糖链结构决定因素对阳离子非依赖性甘露糖 6-磷酸受体结合和重组蛋白的细胞摄取。
Bioconjug Chem. 2013 Dec 18;24(12):2025-35. doi: 10.1021/bc400365a. Epub 2013 Nov 12.
Zotero 插件